NCT06955169 2026-02-17
MOMENTUM-1
RTOG Foundation, Inc.
Phase 2 Recruiting
Clinical Trials
8 trialsNCT06326190 2025-09-16
LUMEN-1
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Recruiting
NCT00006119 2021-02-21
Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma
UNICANCER
Phase 2 Completed
NCT00706810 2017-04-13
Combination of Hydroxyurea and Verapamil for Refractory Meningiomas
University of Utah
Phase 2 Completed
NCT00003590 2016-05-20
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
SWOG Cancer Research Network
Phase 2 Completed
NCT00904735 2013-08-12
Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00615927 2013-03-15
Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)
Duke University
Phase 2 Completed
NCT00290771 2011-05-16
Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)
Novartis
Phase 2 Terminated